Reducing Loss of Calcium Homeostasis to Treat Aging in Mice

Key Takeaways

• Calcium imbalance drives S100A6 accumulation, triggering DNA damage and SASP
• Mianserin lowers intracellular Ca2+ by blocking HTR2B/2C receptors
• Treated mice show 17% longer lifespan and improved health markers
• Approach targets senescent cell behavior rather than cell elimination
• Existing antidepressant could accelerate anti‑aging drug development pipelines

Pulse Analysis

Calcium homeostasis is a cornerstone of cellular health, regulating processes from muscle contraction to gene expression. In aging tissues, the authors demonstrate that loss of calcium balance leads to excess S100A6, which recruits CacyBP to ubiquitinate PARP1, precipitating DNA damage and the release of cytoplasmic chromatin fragments. These fragments ignite the cGAS‑STING‑NF‑κB cascade, fueling the senescence‑associated secretory phenotype that drives chronic inflammation and tissue decline. Understanding this cascade links a classic electrolyte disturbance to the molecular hallmarks of aging.

The study repurposes mianserin, a tetracyclic antidepressant, as a calcium‑modulating agent. By antagonizing serotonin receptors HTR2B and HTR2C, mianserin reduces intracellular Ca2+ levels, curbing S100A6 accumulation and downstream DNA damage. In both progeroid and naturally aging mouse models, chronic mianserin treatment not only attenuated SASP factors but also produced a 17% increase in median lifespan and measurable improvements in frailty, metabolic health, and organ function. These preclinical outcomes position calcium regulation as a viable anti‑aging intervention, complementing the growing field of senolytics that aim to eliminate senescent cells.

From a market perspective, leveraging an already approved drug accelerates the translational timeline, sidestepping many early‑stage safety hurdles. Investors and biotech firms focused on longevity can now explore combination regimens that pair senolytics with calcium‑homeostasis modulators to achieve synergistic benefits. Moreover, the mechanistic clarity provided by the S100A6‑CacyBP‑PARP1 axis offers biomarkers for early‑phase trials, facilitating regulatory pathways. As the longevity sector matures, strategies that modify senescent cell behavior rather than destroy them may broaden therapeutic options and attract broader clinical adoption.